Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (n = 72, cohort 1), HER2-low (n = 74, cohort 2) and HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosele, Fernanda, Deluche, Elise, Lusque, Amelie, Le Bescond, Loïc, Filleron, Thomas, Pradat, Yoann, Ducoulombier, Agnes, Pistilli, Barbara, Bachelot, Thomas, Viret, Frederic, Levy, Christelle, Signolle, Nicolas, Alfaro, Alexia, Tran, Diep T. N., Garberis, Ingrid Judith, Talbot, Hugues, Christodoulidis, Stergios, Vakalopoulou, Maria, Droin, Nathalie, Stourm, Aurelie, Kobayashi, Maki, Kakegawa, Tomoya, Lacroix, Ludovic, Saulnier, Patrick, Job, Bastien, Deloger, Marc, Jimenez, Marta, Mahier, Celine, Baris, Vianney, Laplante, Pierre, Kannouche, Patricia, Marty, Virginie, Lacroix-Triki, Magali, Diéras, Veronique, André, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427426/
https://www.ncbi.nlm.nih.gov/pubmed/37488289
http://dx.doi.org/10.1038/s41591-023-02478-2

Ejemplares similares

Ejemplares similares